Actively Recruiting
Celecoxib in Parkinson Disease as Adjuvant Therapy
Led by Tanta University · Updated on 2025-12-05
80
Participants Needed
1
Research Sites
53 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Parkinson's disease (PD) is a chronic neurodegenerative disease clinically characterized by bradykinesia, hypokinesia, rigidity, resting tremor, and postural instability. These motor manifestations are attributed to the degeneration and selective loss of dopaminergic neurons in the substantia nigra pars compacta (SNpc), leading to a dopamine (DA) deficiency in the striatum. Neuroinflammation is considered one of the most important factors contributing critically to pathophysiology of PD . Recently, high mobility group box-1 (HMGB1) protein has been encoded as a potential inflammatory biomarker in PD
CONDITIONS
Official Title
Celecoxib in Parkinson Disease as Adjuvant Therapy
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age 65 18 years
- Both male and female will be included
- Patients diagnosed with PD according to Unified Parkinson's Disease Rating Scale
You will not qualify if you...
- Breast feeding
- Patients with significant liver and kidney function abnormalities
- Alcohol and / or drug abusers
- Patients with known allergy to the study medications
- Patients with known allergy to sulfonamides (cross hypersensitivity with celecoxib)
- Pregnant women and women with planned pregnancy
- Patients who are currently using other anti-inflammatory drugs
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Tanta Unuversity
Tanta, Egypt, 31527
Actively Recruiting
How is the study designed?
Study Type
INTERVENTIONAL
Masking
DOUBLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here